Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126197301 | 12619730 | 1 | I | 20160726 | 20160803 | 20160803 | EXP | PHHY2016CN104088 | SANDOZ | LIU N, ZHANG K, LI G. ONE CASE REPORT OF QT INTERVAL PROLONGATION INDUCED BY CONVENTIONAL DOSAGE OF AMIODARONE. PHARMACEUTICAL CARE AND RESEARCH (CHINA). 2016;16(2):97 AND 10 | 71.00 | YR | F | Y | 48.00000 | KG | 20160803 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126197301 | 12619730 | 1 | PS | ATORVASTATIN | ATORVASTATIN | 1 | Unknown | 40 MG, UNK, EVERY NIGHT | Y | 77575 | 40 | MG | |||||||
| 126197301 | 12619730 | 2 | I | ATORVASTATIN | ATORVASTATIN | 1 | Unknown | 20 MG, UNK, EVERY NIGHT | Y | 77575 | 20 | MG | |||||||
| 126197301 | 12619730 | 3 | I | TICAGRELOR | TICAGRELOR | 1 | Unknown | 90 MG, BID | U | 0 | 90 | MG | BID | ||||||
| 126197301 | 12619730 | 4 | I | TICAGRELOR | TICAGRELOR | 1 | U | 0 | |||||||||||
| 126197301 | 12619730 | 5 | I | TICAGRELOR | TICAGRELOR | 1 | U | 0 | |||||||||||
| 126197301 | 12619730 | 6 | I | AMIODARONE | AMIODARONE | 1 | Oral | 0.2 G, TID | Y | 0 | .2 | G | TID | ||||||
| 126197301 | 12619730 | 7 | I | AMIODARONE | AMIODARONE | 1 | Oral | 0.2 G, BID | Y | 0 | .2 | G | BID | ||||||
| 126197301 | 12619730 | 8 | C | ASPIRIN//ACETYLSALICYLIC ACID | ASPIRIN | 1 | Unknown | U | 0 | ||||||||||
| 126197301 | 12619730 | 9 | C | ASPIRIN//ACETYLSALICYLIC ACID | ASPIRIN | 1 | U | 0 | |||||||||||
| 126197301 | 12619730 | 10 | C | ASPIRIN//ACETYLSALICYLIC ACID | ASPIRIN | 1 | U | 0 | |||||||||||
| 126197301 | 12619730 | 11 | C | METOPROLOL. | METOPROLOL | 1 | Unknown | 12.5 G, BID | U | 0 | 12.5 | G | TABLET | BID | |||||
| 126197301 | 12619730 | 12 | C | DIGOXIN. | DIGOXIN | 1 | Unknown | 0.125 MG, QD | U | 0 | .125 | MG | QD | ||||||
| 126197301 | 12619730 | 13 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Unknown | 12.5 MG, QD | U | 0 | 12.5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126197301 | 12619730 | 1 | Blood cholesterol |
| 126197301 | 12619730 | 3 | Platelet disorder |
| 126197301 | 12619730 | 4 | Anticoagulant therapy |
| 126197301 | 12619730 | 5 | Vasodilatation |
| 126197301 | 12619730 | 6 | Atrial fibrillation |
| 126197301 | 12619730 | 8 | Platelet disorder |
| 126197301 | 12619730 | 9 | Anticoagulant therapy |
| 126197301 | 12619730 | 10 | Vasodilatation |
| 126197301 | 12619730 | 11 | Ventricular fibrillation |
| 126197301 | 12619730 | 12 | Cardiac disorder |
| 126197301 | 12619730 | 13 | Diuretic therapy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126197301 | 12619730 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126197301 | 12619730 | Drug interaction | |
| 126197301 | 12619730 | Electrocardiogram QT prolonged |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |